Douglas Kling - NewAmsterdam Pharma Chief Officer
| NAMS Stock | 21.77 0.99 4.76% |
Executive
Douglas Kling is Chief Officer of NewAmsterdam Pharma
| Age | 52 |
| Phone | 31 35 206 2971 |
| Web | https://www.newamsterdampharma.com |
Douglas Kling Latest Insider Activity
Tracking and analyzing the buying and selling activities of Douglas Kling against NewAmsterdam Pharma stock is an integral part of due diligence when investing in NewAmsterdam Pharma. Douglas Kling insider activity provides valuable insight into whether NewAmsterdam Pharma is net buyers or sellers over its current business cycle. Note, NewAmsterdam Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell NewAmsterdam Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Douglas Kling few days ago Disposition of 5148 shares by Douglas Kling of NewAmsterdam Pharma at 21.93 subject to Rule 16b-3 | ||
Douglas Kling few days ago Disposition of 23815 shares by Douglas Kling of NewAmsterdam Pharma at 23.46 subject to Rule 16b-3 |
NewAmsterdam Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2927) % which means that it has lost $0.2927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4737) %, meaning that it created substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dilip Kodira | PureTech Health PLC | N/A | |
| Alice PharmD | Inventiva Sa | 54 | |
| Paul Bullock | Replimune Group | N/A | |
| Eric MBA | PureTech Health PLC | N/A | |
| Anna Gifford | Compass Therapeutics | N/A | |
| Emiko Bryant | PepGen | N/A | |
| James Pennington | Janux Therapeutics | N/A | |
| Kristina Meyer | Inventiva Sa | N/A | |
| Spencer Ball | PureTech Health PLC | N/A | |
| Pascaline Clerc | Inventiva Sa | 45 | |
| Brenda Vreeswyk | Janux Therapeutics | N/A | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| Marc CPA | Crinetics Pharmaceuticals | 45 | |
| Daniel George | Anebulo Pharmaceuticals | 55 | |
| Andrew MD | Merus BV | 58 | |
| Michelle MD | PepGen | 49 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Nathalie Harroy | Inventiva Sa | 58 | |
| David CFA | PepGen | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 |
NewAmsterdam Pharma Leadership Team
Elected by the shareholders, the NewAmsterdam Pharma's board of directors comprises two types of representatives: NewAmsterdam Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NewAmsterdam. The board's role is to monitor NewAmsterdam Pharma's management team and ensure that shareholders' interests are well served. NewAmsterdam Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NewAmsterdam Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Louise Kooij, Treasurer, CFO | ||
| Jim Jacobson, Chief Secretary | ||
| Annie Neild, VP Affairs | ||
| FESC MD, Chief Founder | ||
| Marc MD, Chief Officer | ||
| MSc MBA, Chief Officer | ||
| Lina Gugucheva, Chief Officer | ||
| Sheng Cui, Chief Officer | ||
| Douglas Kling, Chief Officer | ||
| FACC Facp, President CEO | ||
| Bob Rambo, Executive Marketing | ||
| MBA Jones, Chief Officer | ||
| FACC Facc, President, CEO | ||
| Mayur Somaiya, Chief Officer | ||
| Matthew Philippe, Executive Relations |
NewAmsterdam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NewAmsterdam Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 1.91 B | ||||
| Shares Outstanding | 92.39 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 84.04 % | ||||
| Number Of Shares Shorted | 2.99 M | ||||
| Price To Book | 6.15 X | ||||
| Price To Sales | 69.37 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.